David Reardon, MD

Medical Oncology

David Reardon, MD

View Full Profile

Related Videos

ASCO26: David Reardon, MD, Glioblastoma Vaccine Video

ASCO26: David Reardon, MD, Glioblastoma Vaccine

Dana-Farber Cancer Institute's Dr. David Reardon reports on data showing a phase 1 trial looking at a personalized vaccine plus pembrolizumab sparked tumor-targeting T cells in glioblastoma and was linked to longer survival in immune responders.

ASCO22: Glioblastoma research by David Reardon, MD Video

ASCO22: Glioblastoma research by David Reardon, MD

Glioblastoma study shows combination immunotherapy is safe and early data on effectiveness is encouraging. Dana-Farber's David Reardon, MD, details more at #ASCO22 about the combination of a potent vaccine platform with immune checkpoint blockade.